Your browser doesn't support javascript.
loading
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Freedman, Rachel A; Gelman, Rebecca S; Anders, Carey K; Melisko, Michelle E; Parsons, Heather A; Cropp, Anne M; Silvestri, Kelly; Cotter, Christine M; Componeschi, Kathryn P; Marte, Juan M; Connolly, Roisin M; Moy, Beverly; Van Poznak, Catherine H; Blackwell, Kimberly L; Puhalla, Shannon L; Jankowitz, Rachel C; Smith, Karen L; Ibrahim, Nuhad; Moynihan, Timothy J; O'Sullivan, Ciara C; Nangia, Julie; Niravath, Polly; Tung, Nadine; Pohlmann, Paula R; Burns, Robyn; Rimawi, Mothaffar F; Krop, Ian E; Wolff, Antonio C; Winer, Eric P; Lin, Nancy U.
Afiliación
  • Freedman RA; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Gelman RS; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Anders CK; 2 University of North Carolina at Chapel Hill, Chapel Hill, NC.
  • Melisko ME; 3 University of California at San Francisco, San Francisco, CA.
  • Parsons HA; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Cropp AM; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Silvestri K; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Cotter CM; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Componeschi KP; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Marte JM; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Connolly RM; 4 Johns Hopkins School of Medicine, Baltimore, MD.
  • Moy B; 5 Massachusetts General Hospital, Boston, MA.
  • Van Poznak CH; 6 University of Michigan, Ann Arbor, MI.
  • Blackwell KL; 7 Duke University Medical Center, Durham, NC.
  • Puhalla SL; 8 University of Pittsburgh Cancer Institute, Pittsburgh, PA.
  • Jankowitz RC; 8 University of Pittsburgh Cancer Institute, Pittsburgh, PA.
  • Smith KL; 4 Johns Hopkins School of Medicine, Baltimore, MD.
  • Ibrahim N; 9 The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Moynihan TJ; 10 Mayo Clinic, Rochester, MN.
  • O'Sullivan CC; 10 Mayo Clinic, Rochester, MN.
  • Nangia J; 11 Baylor College of Medicine, Houston, TX.
  • Niravath P; 11 Baylor College of Medicine, Houston, TX.
  • Tung N; 12 Beth Israel Deaconess Medical Center, Boston, MA.
  • Pohlmann PR; 13 Lombardi Comprehensive Cancer Center, Washington, DC.
  • Burns R; 14 The Emmes Corporation, Rockville, MD.
  • Rimawi MF; 11 Baylor College of Medicine, Houston, TX.
  • Krop IE; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Wolff AC; 4 Johns Hopkins School of Medicine, Baltimore, MD.
  • Winer EP; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Lin NU; 1 Dana-Farber Cancer Institute, Boston, MA.
J Clin Oncol ; 37(13): 1081-1089, 2019 05 01.
Article en En | MEDLINE | ID: mdl-30860945
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: J Clin Oncol Año: 2019 Tipo del documento: Article País de afiliación: Marruecos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: J Clin Oncol Año: 2019 Tipo del documento: Article País de afiliación: Marruecos